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Background: In Barrett’s oesophagus (BO), squamous epithelium is replaced by specialised intestinal
epithelium (SIE). Transcription factors associated with intestinal differentiation, such as CDX2, may be
involved in BO development.
Aim: To investigate CDX2 expression in BO, squamous epithelium, and oesophageal adenocarcinoma
(ADC).
Methods: CDX2 expression was assessed in 245 samples—167 biopsies of the columnar lined segment
and 38 squamous epithelial biopsies of 39 patients with histologically confirmed BO (10 with ADC). Forty
biopsies from 20 patients with reflux oesophagitis (RO) without BO were also evaluated. CDX2 protein
was investigated immunohistochemically in 138 biopsies from 16 patients with BO, four with ADC, and 20
with RO. Cdx2 and Muc2 mRNA were detected semiquantitatively using 88 BO biopsies and squamous
epithelium from 19 BO patients, and when present from ADC.
Results: SIE was present in 53/79 biopsies from the columnar lined segment; CDX2 protein was seen in all
epithelial cells, but not in biopsies containing only gastric metaplastic epithelium (26/79), or in squamous
epithelium (0/40) of patients with RO. Cdx2 mRNA was detected in all biopsies with goblet cell specific
Muc2 transcription—indicative of SIE. Low Cdx2 mRNA expression was seen in 6/19 squamous
epithelium samples taken 5 cm above the squamocolumnar junction of BO patients.
Conclusion: CDX2 protein/mRNA is strongly associated with oesophageal SIE. Cdx2 mRNA was present
in the normal appearing squamous epithelium of one third of BO patients, and may precede
morphological changes seen in BO. Therefore, pathways that induce Cdx2 transcription in squamous
epithelial cells may be important in BO development.
B
arrett’s oesophagus (BO) is a complication of chronic
gastro–oesophageal reflux disease (GORD). Although
20–30% of the Western population has regular GORD
related complaints,1 it is unclear why only 3–5% of these
patients develop long segment BO.2 BO has a prevalence of
0.03% in the Western population,3 and its development in
patients with GORD is associated with obesity at a young
age,4 increased duodeno–gastro–oesophageal reflux,5 6 com-
plaints at an earlier age,5 a familiar predisposition,7 and a
combination of obesity, presence of a hiatal hernia, and male
sex.6 Patients with BO have an increased risk of developing
adenocarcinoma of the oesophagus, with an annual inci-
dence of 0.5% each year.8 Once these patients have developed
adenocarcinoma, the prognosis is poor, with a five year
survival rate of 5–20%.9
‘‘Transcription factors that play an important role in
normal intestinal differentiation may also play a role in the
development of specialised intestinal epithelium in the
oesophagus’’
BO is characterised by the metaplastic replacement of
squamous epithelial cells of the lower part of the oesophagus
by specialised intestinal epithelium (SIE), which is associated
with the presence of goblet cells and the expression of
intestinal markers such as MUC2,10 alkaline phosphatase,11
villin,12 and sucrase isomaltase.13 The genetic events respon-
sible for this process are largely unknown.
Transcription factors that play an important role in normal
intestinal differentiation may also play a role in the
development of SIE in the oesophagus. CDX2 is such a
transcription factor, and belongs to the caudal related
homeobox gene family.14 CDX2 expression in the gastro-
intestinal tract is intestine specific, with a tightly regulated
anterior boundary in the duodenum.15 CDX2 is involved in
early differentiation and the maintenance of intestinal
epithelial cells, characterised by the formation of multi-
layered structures with microvilli.14 CDX2 also induces
intestine specific transcription of the genes encoding
MUC2, alkaline phosphatase, and sucrase isomaltase.16–18
Therefore, CDX2 is thought to be an important factor in the
development and differentiation of intestinal epithelium.19 20
Because BO is characterised by the development of SIE in
the oesophagus, CDX2 may also play a role in the develop-
ment of BO. To investigate whether CDX2 expression is
associated with BO, and whether its expression may precede
the morphological changes seen in BO, we determined its
expression in the columnar epithelium of patients with BO,
in squamous epithelium of patients with reflux oesophagitis
only, and in oesophageal adenocarcinoma. Here, we show
that CDX2 is expressed in SIE, but not in squamous
epithelium of patients with reflux oesophagitis and in gastric
metaplastic epithelium. Furthermore, Cdx2 mRNA was also
detected in the squamous epithelium of one third of patients
with BO, suggesting that CDX2 is indeed involved in the
development of BO, and that its expression may precede the
morphological changes seen in BO.
Abbreviations: BO, Barrett’s oesophagus; GORD, gastro-oesophageal
reflux disease; PCR, polymerase chain reaction; RT, reverse
transcription; SIE, specialised intestinal epithelium
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MATERIALS AND METHODS
Patients and materials
CDX2 expression was analysed in 245 oesophageal samples.
These consisted of 167 biopsies of the columnar lined
segment and 38 squamous epithelial biopsies of 39 patients
with histologically confirmed BO, of whom 10 also had an
oesophageal adenocarcinoma, and 40 biopsies of 20 patients
with reflux oesophagitis without BO.
CDX2 protein expression was analysed by immunohisto-
chemistry (table 1) in 138 biopsies, consisting of 79 biopsies
of the columnar lined segment, 19 oesophageal adenocarci-
nomas, and 40 squamous epithelium biopsies of the
oesophagus. The four quadrant biopsies taken at 2 cm
intervals from the columnar lined segment were pooled,
formalin fixed, and paraffin wax embedded. Biopsies of the
colon were used as a positive control.
Biopsies from a second group of patients, not related to the
first group, were used for mRNA analysis, because this
analysis could not be performed on the formalin fixed,
paraffin wax embedded samples. One hundred and seven
oesophageal biopsies were collected at endoscopy from 19
patients with BO (table 1), six of whom also had oesophageal
adenocarcinoma. Biopsy specimens were obtained from the
columnar mucosa of the oesophagus (n = 38), the adeno-
carcinoma if present (n = 12), and the squamous epithe-
lium—5 cm above the neosquamous–columnar junction
(n = 38). For each of these locations, the biopsies from
each location (two of the BO segment, two of the squamous
epithelium, and when present two of the oesophageal
adenocarcinoma) of individual patients were pooled, snap
frozen, and used for RNA extraction (see below). An
additional biopsy was taken next to the previous biopsies
from the BO segment, and was used for the histological
evaluation of the presence of SIE (n = 19). All columnar
segments lining the oesophagus at endoscopy of both groups
of patients were at least 3 cm in length or more. Biopsies of
the colon were used as positive controls for Cdx2 mRNA
analysis. Our study was approved by the central committee
on research involving human subjects in The Netherlands in
2002.
Histological analyses
Sections from the biopsies and part of the biopsies taken for
RNA analysis were stained with haematoxylin and eosin and
evaluated for the presence of SIE and/or adenocarcinoma.
Staining with Alcian blue at pH 2.5 was performed to
facilitate the detection of mucin producing goblet cells.21
The inflammatory response in biopsies of patients with reflux
oesophagitis and BO, which were used for immunohisto-
chemistry, was graded by the Ismail-Beigi classification22 for
squamous epithelium and by the updated Sydney system23 24
for columnar epithelium.
Immunohistochemistry
Biopsy samples were serially sectioned at 4 mm, mounted on
adhesive slides, dried overnight at 37 C˚, and dewaxed with
xylene. Antigen retrieval was performed in 10mM monocitric
acid (pH 6.0) at 100 C˚ for 15 minutes. After cooling, the
samples were blocked with non-immune serum for 30
minutes. The sections were stained using the primary
antibody against CDX2 (1/100 dilution; Biogenex, San
Ramon, California, USA), followed by the addition of a
biotinylated rabbit secondary antibody (Dako, Glostrup,
Denmark) and streptavidin–alkaline phosphatase complex
(Dako). A red colour was developed using new fuchsine
substrate.
Semiquantitative RT-PCR
Total RNA was isolated using TRIzol-reagent (Invitrogen,
Groningen, The Netherlands), and the remaining chromoso-
mal DNA was subsequently removed with the DNA free RNA
kit (Zymo, Orange, California, USA). Semiquantitative
reverse transcription polymerase chain reaction (RT-PCR)
was performed using intron spanning primers for Cdx2 (59-
CCCAGCGGCCAGCGGCGAAACCTGT/59-TATTTGTCTTTTGTC-
CTGGTTTTCA) and Muc2 (59-CAGGATGGCGCCTTCTGCTA/
59-ATGCTGCTCCAAGCTGAGGT). Amounts of Cdx2 and
Muc2 mRNA were standardised to those of b actin using
the b actin primers 59-CAAGGCCAACCGCGAGAAG and 59-
CAGGGTACATGGTGGTGCC. cDNA was synthesised with the
use of avian myeloma virus reverse transcriptase (Promega,
Madison, Wisconsin, USA). Primers were annealed by cool-
ing down from 70 C˚ to room temperature, followed by cDNA
synthesis by incubation for 30 minutes at 42 C˚. PCRs (total
volume of 25 ml) contained 1 ml of the cDNA solution,
16PCR core buffer (Promega), 2mM MgCl2, 0.4mM forward
and reverse primer, 200mM of each nucleotide (Promega),
and 0.02 U/ml Taq polymerase (Promega).
Table 1 Patient characteristics
Patient characteristics No of patients No of biopsies Mean age (SD) Male %
First group
IHC Adenocarcinoma 4 19 78.5 (2.7) 75%
Barrett’s oesophagus 16 79 70.8 (14) 66%
Reflux oesophagitis 20 40 61.8 (11.6) 71%
Second group
RT-PCR Adenocarcinoma 6 12 68.9 (11.5) 57%
Barrett’s oesophagus 19 76 65.1(15.1) 55%
IHC, immunohistochemistry; RT-PCR, reverse transcriptase polymerase chain reaction.
Table 2 Histological classification of inflammation
Reflux oesophagitis Barrett’s oesophagus
Histological classification Histological classification
Ismail-Beigi22 Updated Sydney24 Acute Chronic
1 7/20 (35%) 1 4/16 (25%) 5/16 (31%)
2 7/20 (35%) 2 7/16 (44%) 7/16 (44%)
3 6/20 (30%) 3 5/16 (31%) 4/16 (25%)
4 0 0
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PCR conditions were 35 cycles at 94 C˚ for 30 seconds, 55 C˚
for 30 seconds, and 72 C˚ for one minute. PCR products were
size separated on a 2% agarose gel and stained with ethidium
bromide. Band size and intensity were determined with the
Kodak 1D software version 3.5 (Kodak, Rochester, New York,
USA). Bands were standardised against the b actin house-
keeping gene, as described previously.25
Statistical analyses
All continuous variables were expressed as mean (SEM).
Statistical analyses were done by means of the Fisher’s exact
test for immunohistochemistry and the Mann Whitney U test
for the semiquantitative RT-PCR data. A two sided p value
, 0.05 was considered significant.
RESULTS
Histology
SIE was seen in 53 of 79 (67%) biopsies from the columnar
lined segment and was absent in 26 (33%) biopsies. The
biopsies without SIE comprised gastric type (cardiac or
fundic type) epithelium. SIE was also absent in all 40 reflux
oesophagitis biopsies, which contained only squamous
epithelium in all biopsies.
The inflammatory response in BO was graded according to
the updated Sydney system, in which the inflammation is
divided into four categories based on an acute component
(numbers of neutrophils and eosinophils) and a chronic
component (mononuclear cell count) in the epithelium.24
This system was originally developed for glandular epithe-
lium of the stomach, but has also been shown to be useful in
the inflammatory classification of BO.24 The acute component
of inflammation in BO samples ranged from mild to severe in
most biopsies, with four patients with BO having grade 1,
seven grade 2, and five grade 3 inflammation, according to
the updated Sydney classification (table 2). The chronicity of
the inflammation ranged from mild to severe, with five
patients with BO having grade 1, seven having grade 2, and
four having grade 3. The inflammation in the 40 squamous
epithelium biopsies of the 20 patients with reflux oesopha-
gitis was graded as grade 1 in seven patients, grade 2 in
seven, and grade 3 in six, according to the Ismail-Beigi
classification (table 2). For this reason, we assumed that the
biopsies were representative of the whole spectrum of
inflammation in both BO and reflux oesophagitis.
CDX2 expression
All oesophageal biopsies (53 SIE, 26 gastric type, 19
oesophageal adenocarcinoma, and 40 inflamed squamous
epithelium) were analysed for the presence of the CDX2
protein by immunohistochemistry. All 53 biopsies with SIE
had positive nuclear staining for CDX2 in the epithelium
(fig 1A). This staining was associated (p , 0.001) with the
presence of goblet cells, as detected in serially sectioned slides
by staining with Alcian blue at pH 2.5 (fig 1B). Nuclear CDX2
expression was also seen in all 19 oesophageal adenocarci-
noma samples (fig 1C). Cytoplasmic staining for CDX2 was
not seen. Nuclear or cytoplasmic staining for the CDX2
protein was absent in the 26 gastric type epithelium biopsies
and in the 40 squamous epithelium biopsies (fig 1D).
Molecular analysis
The presence of Cdx2 mRNA was evaluated in the second
group of 19 patients with BO by RT-PCR, and this was
normalised for b actin transcription (fig 2A). For all 19
patients, the presence of SIE was confirmed in the biopsies
taken adjacent to those used in the transcriptional analysis.
Cdx2 mRNA was detected in 13 of 19 BO segments and in
four of six oesophageal adenocarcinomas (fig 2B). The
amounts of Cdx2 mRNA did not differ significantly between
BO and oesophageal adenocarcinoma (p = 0.9) (fig 2B).
To determine whether the expression of Cdx2 precedes the
morphological changes seen in BO, the amounts of Cdx2
mRNA were also determined in squamous epithelium
biopsies obtained 5 cm above the neosquamous–columnar
junction of patients with BO (fig 3). Low amounts of Cdx2
mRNA were present in six of 19 samples of squamous
epithelium (fig 3). The relative amounts of Cdx2 mRNA in
the squamous epithelium were significantly lower (p , 0.01)
than those seen in BO tissue (fig 2B). The presence of goblet
cells, characteristic of BO, was evaluated by the detection of
goblet cell specific Muc2 mRNA. Cdx2 mRNA was present in
Figure 1 CDX2 protein in Barrett’s
oesophagus, oesophageal
adenocarcinoma, and reflux
oesophagitis. (A) Positive nuclear
staining (red) for CDX2 was seen in 16
of 16 samples of Barrett’s oesophagus.
A representative slide from patient 10 is
shown. (B) The presence of CDX2 was
associated with goblet cells, which are
characteristic of Barrett’s oesophagus,
as was shown using Alcian blue
(pH 2.5) staining of a serially sectioned
slide of the same patient. (C) CDX2 was
also present in four of four
adenocarcinomas; a representative
slide from patient 3 is shown. (D) CDX2
was absent in the squamous epithelium
of all patients with reflux oesophagitis
(0 of 20).
CDX2 expression in Barrett’s oesophagus 1065
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all Muc2 positive samples. Furthermore, samples without the
presence of Cdx2 mRNA did not contain Muc2 transcripts.
Muc2 mRNA was absent in only three BO samples with Cdx2
transcription (fig 3). In addition, Muc2 transcripts were not
detected in the squamous epithelium samples.
DISCUSSION
We have shown that CDX2 protein is present in BO
containing SIE, as was recently reported by others.26 27
CDX2 expression was also detected in oesophageal adeno-
carcinoma. In contrast, no CDX2 protein was seen in biopsies
containing gastric type epithelium of the distal oesophagus
taken from patients with BO, or in the squamous epithelium
of patients with reflux oesophagitis without BO. However,
low amounts of Cdx2 mRNA were detected in approximately
one third of the squamous epithelium samples of patients
with BO. The presence of Cdx2 mRNA also correlated with
goblet cell specific Muc2 mRNA in BO samples (fig 3).
The homeobox protein CDX2 is involved in the differentia-
tion and maintenance of intestinal epithelium.14 Expression
of CDX2 is detected at the time of morphogenesis in the
visceral endoderm of mouse intestine,28 and continues to be
present throughout adulthood, but then is normally
restricted to the intestine.29 It is detectable in the crypts of
the intestine and in the villi,15 and is thought to be a key
regulator of intestinal differentiation.19 Exogenous expression
of CDX2 in IEC6 cells, an undifferentiated rat intestinal cell
line that does not express CDX2, causes differentiation of
IEC6 cells into goblet cells and absorptive enterocytes.14
Similar observations have been made in an animal model,
in which ectopic expression of CDX2 induced the develop-
ment of metaplastic changes of the gastric antrum, and in
Helicobacter pylori related intestinal metaplasia of the human
stomach.30 31 These metaplastic changes of the mouse gastric
antrum were also characterised by the development of goblet
cells and absorptive enterocytes, and the expression of
intestine specific proteins such as MUC2, alkaline phospha-
tase, villin, guanylyl cyclase C, and trefoil factor 3.21 In
contrast, heterozygous CDX2 knockout mice developed
polyp-like lesions in their colon during the first 3 months
of life, which lacked CDX2 expression.32 These lesions were
composed of heterotopic, well differentiated, stratified
squamous epithelium, stomach, and small intestinal
mucosa.33 It was concluded that CDX2 directs epithelial
differentiation towards a caudal phenotype. For these
reasons, CDX2 expression is thought to be an early marker
of intestinal differentiation, and may therefore play a role in
the development of SIE in the lower part of the oesophagus,
as seen in BO.
‘‘We hypothesise that inflammation in the oesophagus
caused by duodeno–gastro–oesophageal reflux induces
CDX2 expression in a subset of patients’’
Although all additional biopsies taken from the BO
segment for histological evaluation in the group of patients
in whom Cdx2 mRNA was determined showed SIE, Cdx2
mRNA was not detected in six of 19 (32%) BO segments. In
the biopsies taken from these segments, Muc2 transcription
was absent, which suggests that goblet cells were not present
in these samples. Because goblet cells are a hallmark of BO,
these biopsies may have contained another type of columnar
epithelium, probably gastric type epithelium, as was detected
in 26 of 79 biopsies of the BO segment in our study. This is in
agreement with findings in another study, which reported
that goblet cells were only found in 51% of patients with
Figure 2 Cdx2 mRNA in Barrett’s oesophagus, squamous epithelium,
and oesophageal adenocarcinoma. (A) Cdx2 mRNA was detected by
reverse transcription polymerase chain reaction (95 bp fragment) in four
of six oesophageal adenocarcinoma (ADC) samples, in 13 of 19
Barrett’s oesophagus (BO) samples, in six of 19 squamous epithelium
(Sq) samples, and in colon control tissue (Co). (B) Relative amounts of
Cdx2 mRNA in squamous epithelium, BO, and ADC. Amounts of Cdx2
mRNA were normalised against b actin. The mean Cdx2 mRNA values
in squamous epithelium (n = 6) were significantly lower than those seen
in BO (n = 13) (p , 0.01). The relative amounts of Cdx2 mRNA did not
differ significantly between BO (n = 13) and ADC (n = 4) (not
significant; p , 0.1).
Figure 3 Schematic overview of the distal oesophagus, summarising
the transcription of Cdx2 mRNA and goblet cell specific Muc2 mRNA in
biopsies taken from the Barrett’s segment and the squamous epithelium
of patients with Barrett’s oesophagus.
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3–4 cm columnar-like epithelium of the oesophagus on a first
endoscopy.34 This increased to 88.9% after three endosco-
pies.34 This suggests that the absence of SIE in the biopsies
taken from the columnar lined segment might be the result
of sampling error. Because in our study only one of the six
patients negative for Cdx2 mRNA had an oesophageal
adenocarcinoma, and no dysplasia was seen in the adjacent
biopsies taken for routine screening in the other five patients,
it is unlikely that a neoplasm that is associated with a
decreased number of goblet cells was present in these biopsies.
To assess whether CDX2 is an early marker for metaplastic
replacement in the oesophagus, Cdx2 mRNA expression was
also determined in reflux exposed squamous epithelium of
patients with BO. Low amounts of Cdx2 mRNA were indeed
seen in six of the 19 squamous epithelium samples tested
(fig 3). In addition, transcription of Muc2 was not detected in
these samples, which excludes the possibility that SIE was
covered by a stratified epithelial layer. This indicates that
healthy appearing squamous epithelium 5 cm above the
squamo–columnar junction of the oesophagus in a subset of
patients with columnar metaplasia of the distal oesophagus
may already have undergone molecular changes, which may
make them prone to the development of SIE, although this
needs to be determined in a longitudinal follow up study of
patients with reflux oesophagitis without BO. Patient to
patient variation in the extent of reflux, the severity of
inflammation, and the effect of the medication used, may
explain why not all squamous epithelium samples of patients
with BO contained detectable amounts of Cdx2 mRNA.
The development of BO is associated with the pathological
reflux of acid35 and/or bile.36 Taken together with recent
reports that CDX2 expression can be induced in keratinocytes
by prolonged exposure to acid,37 Cdx2 transcription may be
an early step in the metaplastic replacement of oesophageal
squamous epithelium by SIE. We hypothesise that inflam-
mation in the oesophagus caused by duodeno–gastro–
oesophageal reflux induces CDX2 expression in a subset of
patients. Pathways involved in de novo CDX2 expression in
oesophageal squamous epithelium may be important for the
development of BO. Elucidating these pathways may result in
a greater understanding of why only a subset of patients with
GORD develop BO.
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Take home messages
N The expression of CDX2 protein and mRNA is strongly
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H pylori strains from gastric MZBL have common genetic marker
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R
esearchers may have discovered a key determinant of a rare complication of gastric
lymphoma—a virulence sequence of Helicobacter pylori—in a comparative molecular
study.
They looked for genetic markers in H pylori strains isolated from patients with gastric
extranodal marginal zone B cell lymphoma (MZBL) of the mucosa-associated lymphoid
tissue (MALT)-type and strains from age matched patients with gastritis only. They used
subtractive hybridisation, which allows genes or sequences from isolated strains to be
compared with a chosen control strain. The two strains used were a ‘‘tester’’ gastric MZBL
strain and a ‘‘driver’’ gastritis strain chosen as the control, which had six known H pylori
virulence genes in common.
Two open reading frames (ORFs) from the hybridisation were significantly linked with
gastric MZBL over gastritis strains: JHP950 (74% v 49%) and JHP1462 (26% v 3%). JHP950
proved specific for gastric MZBL when tested against a group of strains from patients with
duodenal ulcer and patients with adenocarcinoma, with significant prevalences (49% and
39%, respectively), and is therefore the candidate marker for gastric MZBL. Both ORFs coded
for unknown products.
The researchers tested 43 strains from patients with gastric MZBL, 39 from patients with
gastritis only, 41 from duodenal ulcer, and 28 from gastric adenocarcinoma. All patients
were age matched.
H pylori causes gastric adenoma and MALT lymphoma and also 80% of gastric MZBL.
Bacterial virulence factors may be responsible, but the researchers had previously ruled out
all six H pylori virulence factors and instead investigated genetic variation specific to MZBL
strains.
m Lehours P, et al. Gut 2004;53:931–937.
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